Brief: Relief Therapeutics: NRx Pharmaceuticals Announces Update On Breakthrough Designation For Aviptadil

MindMaze Therapeutics Holding SA

13/06/2022 06:03

June 13 (Reuters) - RELIEF THERAPEUTICS HOLDING SA  RLFB.S :
    * REPORTS THAT ITS U.S. COLLABORATION PARTNER HAS ANNOUNCED
AN
UPDATE ON BREAKTHROUGH DESIGNATION FOR AVIPTADIL
    * NRX PHARMACEUTICALS, INC. HAS ANNOUNCED THAT U.S. FOOD AND
DRUG
ADMINISTRATION ("FDA") HAS DENIED ITS MOST RECENT APPLICATION
SEEKING BREAKTHROUGH THERAPY DESIGNATION ("BTD") FOR AVIPTADIL

Source text for Eikon:  ID:nEQ6QJGrVa 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))